MedPath
NMPA Approval

Recombinant COVID-19 Vaccine(CHO Cell)

国药准字S20220010

February 28, 2023

Drug Information

重组新型冠状病毒蛋白疫苗(CHO细胞)

智克威得

注射剂

0.5mL/瓶,每1次人用剂量为0.5mL,含NCP-RBD蛋白25μg。

生物制品

February 28, 2023

Company Information

Applicant Company

安徽省合肥市高新区明珠大道5008号

Manufacturing Company

合肥市高新区浮山路100号七车间原液生产线、七车间制剂生产线、五车间冻干制剂生产线

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

重组新型冠状病毒蛋白疫苗(CHO细胞) - NMPA 批准文号 | MedPath